152 related articles for article (PubMed ID: 38196558)
1. Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer.
Kawai T; Taguchi S; Nozaki K; Kimura N; Oshina T; Iwaki T; Matsui H; Niimi A; Kamei J; Akiyama Y; Yamada Y; Sato Y; Yamada D; Kaneko T; Sawayanagi S; Nakayama H; Minamimoto R; Yamashita H; Miyazaki H; Fujimura T; Nakagawa T; Kume H
Prostate Int; 2023 Dec; 11(4):239-246. PubMed ID: 38196558
[TBL] [Abstract][Full Text] [Related]
2. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.
Deek MP; Taparra K; Phillips R; Velho PI; Gao RW; Deville C; Song DY; Greco S; Carducci M; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Tran PT; Stish BJ
Eur Urol Oncol; 2021 Jun; 4(3):447-455. PubMed ID: 32536574
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic radiotherapy to oligoprogressive lesions detected with
Onal C; Ozyigit G; Oymak E; Guler OC; Tilki B; Hurmuz P; Akyol F
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3683-3692. PubMed ID: 33693965
[TBL] [Abstract][Full Text] [Related]
5. Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor.
Yoshida S; Takahara T; Arita Y; Ishii C; Uchida Y; Nakagawa K; Toda K; Sakamoto T; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Yoshimura R; Fujii Y
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):376-381. PubMed ID: 31201896
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
7. Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice.
Patel PH; Tunariu N; Levine DS; de Bono JS; Eeles RA; Khoo V; Murray J; Parker CC; Pathmanathan A; Reid A; van As N; Tree AC
Front Oncol; 2022; 12():862995. PubMed ID: 35656509
[TBL] [Abstract][Full Text] [Related]
8. Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer.
Lee JN; Kim MY; Kang JH; Kang JK; Chung JW; Ha YS; Choi SH; Kim BS; Kim HT; Kim TH; Yoo ES; Kim SH; Kwon TG
Investig Clin Urol; 2024 Mar; 65(2):132-138. PubMed ID: 38454822
[TBL] [Abstract][Full Text] [Related]
9. A case of repeat oligoprogressive castration-resistant prostate cancer treated with pulmonary metastasectomy.
Soma T; Yoshida S; Wakejima R; Taguchi T; Fukuda S; Tanaka H; Yokoyama M; Ohashi K; Okubo K; Fujii Y
IJU Case Rep; 2023 Jul; 6(4):216-218. PubMed ID: 37405025
[TBL] [Abstract][Full Text] [Related]
10. Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer.
Suzuki K; Terakawa T; Shigemura K; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Mol Clin Oncol; 2019 Nov; 11(5):523-530. PubMed ID: 31620284
[TBL] [Abstract][Full Text] [Related]
11. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial.
Rans K; Joniau S; Berghen C; Goffin K; Dumez H; Haustermans K; De Meerleer G
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38664137
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
Nadal R; Tsai HL; Sinibaldi VJ; Paller CJ; Antonarakis ES; Denmeade SR; Carducci MA; Eisenberger MA
Prostate; 2016 Apr; 76(5):512-20. PubMed ID: 26689606
[TBL] [Abstract][Full Text] [Related]
13. The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.
Oka T; Hatano K; Okuda Y; Yamamoto A; Uemura T; Yamamichi G; Tomiyama E; Ishizuya Y; Yamamoto Y; Kato T; Kawashima A; Fujita K; Nonomura N
Int J Clin Oncol; 2023 Mar; 28(3):427-435. PubMed ID: 36580184
[TBL] [Abstract][Full Text] [Related]
14. Serum testosterone levels and testosterone 'bounce' phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer.
Tan YG; Quek SZH; Huang HH; Ho HSS; Yuen JSP; Tay KJ; Tuan JKL; Chen K
Urol Oncol; 2021 Dec; 39(12):829.e9-829.e17. PubMed ID: 34023195
[TBL] [Abstract][Full Text] [Related]
15. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.
Heck MM; Thalgott M; Schmid SC; Oh WK; Gong Y; Wang L; Zhu J; Seitz AK; Porst D; Höppner M; Retz M; Gschwend JE; Nawroth R
Prostate; 2016 Sep; 76(13):1160-8. PubMed ID: 27198487
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis.
Valeriani M; Detti B; Fodor A; Caini S; Borghesi S; Trippa F; Triggiani L; Bruni A; Russo D; Saldi S; Di Staso M; Francolini G; Lancia A; Marinelli L; Di Muzio N; Aristei C; Livi L; Magrini SM; Ingrosso G
Radiol Med; 2022 Jan; 127(1):108-116. PubMed ID: 34748151
[TBL] [Abstract][Full Text] [Related]
17. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
[TBL] [Abstract][Full Text] [Related]
18. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
Calderoni L; Maietti E; Farolfi A; Mei R; Louie KS; Groaning M; Fanti S
J Nucl Med; 2023 Jun; 64(6):910-917. PubMed ID: 36635087
[TBL] [Abstract][Full Text] [Related]
19. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
Franzese C; Perrino M; Marzo MA; Badalamenti M; Baldaccini D; D'Agostino G; Marini B; De Vincenzo F; Zucali PA; Scorsetti M
Clin Exp Metastasis; 2022 Jun; 39(3):449-457. PubMed ID: 35190933
[TBL] [Abstract][Full Text] [Related]
20. Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort.
Khoshkar Y; Westerberg M; Adolfsson J; Bill-Axelson A; Olsson H; Eklund M; Akre O; Garmo H; Aly M
BJUI Compass; 2022 Mar; 3(2):173-183. PubMed ID: 35474724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
